Chalkis Health released its 2026 interim report. During the reporting period, the company's total operating revenue was 197 million yuan, and net profit attributable to the parent company was a loss of 65.919 million yuan, a reduction in loss of 8.7841 million yuan compared with the same period last year. Net cash inflow from operating activities was 127 million yuan, an increase of 228 million yuan year-on-year. The company's asset-liability ratio was 104.13%, down 2.66 percentage points year-on-year; gross margin was negative 19.81%; diluted earnings per share was negative 0.09 yuan, an increase of 0.01 yuan year-on-year. Total asset turnover was 0.18 times, up 12.99% year-on-year; inventory turnover was 1.02 times, up 212.38% year-on-year. The number of shareholders was 22,600, and the top ten shareholders held 43.04% of the total share capital.
Xinjiang Chalkis Co LtdNet loss of 65.919 million yuan, though narrowed year-on-year, with negative gross margin and high debt ratio.